Clearside Biomedical (CLSD) News Today $0.87 +0.02 (+2.10%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.88 +0.01 (+0.95%) As of 05/2/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on ThursdayClearside Biomedical (NASDAQ:CLSD) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-clearside-biomedical-inc-stock/)May 3 at 4:30 AM | marketbeat.comClearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences ConferenceMay 1 at 7:05 AM | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Shares Pass Below Fifty Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Shares Cross Below 50-Day Moving Average - Time to Sell?April 30, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Upgraded to Hold at StockNews.comApril 27, 2025 | americanbankingnews.comClearside Biomedical (NASDAQ:CLSD) Shares Pass Below Fifty Day Moving Average - Here's What HappenedClearside Biomedical (NASDAQ:CLSD) Shares Cross Below Fifty Day Moving Average - Here's WhyApril 18, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)Needham & Company LLC restated a "buy" rating and issued a $4.00 target price on shares of Clearside Biomedical in a report on Tuesday.April 10, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for CLSD EarningsClearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Clearside Biomedical in a note issued to investors on Monday, March 31st. HC Wainwright analyst Y. Chen now forecasts that the company will post eApril 5, 2025 | marketbeat.comClearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edgeApril 2, 2025 | uk.investing.comClearside Biomedical (NASDAQ:CLSD) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Monday.April 1, 2025 | marketbeat.comClearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Earns Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a research report on Friday.March 29, 2025 | marketbeat.comNeedham & Company LLC Cuts Clearside Biomedical (NASDAQ:CLSD) Price Target to $4.00Needham & Company LLC dropped their price objective on Clearside Biomedical from $6.00 to $4.00 and set a "buy" rating for the company in a report on Friday.March 29, 2025 | marketbeat.comClearside Biomedical, Inc.: Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 29, 2025 | finanznachrichten.deStifel Nicolaus Sticks to Its Buy Rating for Clearside Biomedical (CLSD)March 29, 2025 | markets.businessinsider.comClearside Biomedical price target lowered to $4 from $6 at NeedhamMarch 28, 2025 | markets.businessinsider.comClearside Biomedical (NASDAQ:CLSD) Issues Quarterly Earnings ResultsClearside Biomedical (NASDAQ:CLSD - Get Free Report) released its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03.March 28, 2025 | marketbeat.comClearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call TranscriptMarch 27, 2025 | seekingalpha.comClearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27, 2025 | globenewswire.comExploring Clearside Biomedical's Earnings ExpectationsMarch 27, 2025 | benzinga.comClearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMarch 24, 2025 | globenewswire.comClearside Biomedical announces presentations on CLS-AXMarch 21, 2025 | markets.businessinsider.comClearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease SummitMarch 20, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Downgraded to "Sell" Rating by StockNews.comStockNews.com cut Clearside Biomedical from a "hold" rating to a "sell" rating in a research note on Tuesday.March 19, 2025 | marketbeat.comShort Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Expands By 34.3%Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 767,400 shares, a growth of 34.3% from the February 13th total of 571,300 shares. Based on an average trading volume of 258,500 shares, the days-to-cover ratio is presently 3.0 days. Approximately 1.1% of the shares of the company are short sold.March 17, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Stock Crosses Below 50 Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Stock Crosses Below Fifty Day Moving Average - What's Next?March 14, 2025 | marketbeat.comClearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025March 12, 2025 | globenewswire.comClearside Biomedical's (CLSD) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a report on Thursday.March 7, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Thursday.March 7, 2025 | marketbeat.comClearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AXMarch 6, 2025 | markets.businessinsider.comClearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMDMarch 6, 2025 | globenewswire.comClearside Biomedical (CLSD) to Release Earnings on TuesdayClearside Biomedical (NASDAQ:CLSD) will be releasing earnings after the market closes on Tuesday, March 11, Financial Modeling Prep reports.March 4, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest UpdateClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 571,300 shares, a drop of 26.5% from the January 31st total of 777,800 shares. Based on an average daily trading volume, of 246,400 shares, the days-to-cover ratio is presently 2.3 days.March 3, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by BrokeragesShares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have been given an average rating of "Buy" by the six ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-montMarch 2, 2025 | marketbeat.comInsider Buying: Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Acquires 15,000 Shares of StockClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) Director Clay Thorp bought 15,000 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were acquired at an average price of $0.92 per share, with a total value of $13,800.00. Following the acquisition, the director now owns 176,141 shares of the company's stock, valued at $162,049.72. This represents a 9.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.February 25, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Director Purchases $13,800.00 in StockFebruary 25, 2025 | insidertrades.comClearside Biomedical’s partner in China granted acceptance of arcatus NDAFebruary 21, 2025 | markets.businessinsider.comClearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular EdemaFebruary 20, 2025 | globenewswire.comClearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trialFebruary 18, 2025 | msn.comClearside Biomedical (NASDAQ:CLSD) Shares Cross Above 50 Day Moving Average - Should You Sell?Clearside Biomedical (NASDAQ:CLSD) Share Price Crosses Above 50-Day Moving Average - Should You Sell?February 15, 2025 | marketbeat.comJonesResearch sees buying opportunity in Clearside ahead of 2025 updatesFebruary 11, 2025 | markets.businessinsider.comClearside reports progress in wet AMD treatment trialsFebruary 10, 2025 | msn.comClearside announces additional data from CLS-AX ODYSSEY Phase 2b trialFebruary 10, 2025 | markets.businessinsider.comClearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 MeetingFebruary 10, 2025 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of "Buy" from BrokeragesClearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) has been assigned an average rating of "Buy" from the six ratings firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objFebruary 5, 2025 | marketbeat.comClearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual ConferenceFebruary 4, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Stock Passes Below 50-Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Share Price Crosses Below 50-Day Moving Average - Here's What HappenedFebruary 4, 2025 | marketbeat.comClearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical ProgramJanuary 28, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving Average - What's Next?Clearside Biomedical (NASDAQ:CLSD) Share Price Passes Below 50 Day Moving Average - What's Next?January 25, 2025 | marketbeat.comClearside Biomedical announces ARCATUS approved in Australia, SingaporeJanuary 23, 2025 | markets.businessinsider.comClearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and SingaporeJanuary 22, 2025 | globenewswire.com Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address CLSD Media Mentions By Week CLSD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLSD News Sentiment▼0.030.73▲Average Medical News Sentiment CLSD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLSD Articles This Week▼33▲CLSD Articles Average Week Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Terns Pharmaceuticals News Today Atea Pharmaceuticals News Today DBV Technologies News Today Solid Biosciences News Today Monopar Therapeutics News Today Nuvectis Pharma News Today Canopy Growth News Today Foghorn Therapeutics News Today Immutep News Today Lifecore Biomedical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLSD) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLSD Stock Free CLSD Stock Alerts